Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- PMID:24887559
- DOI: 10.1016/j.canlet.2014.05.020
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Abstract
The clinical efficacy of the ALK inhibitor crizotinib has been demonstrated in ALK fusion-positive NSCLC; however, resistance to crizotinib certainly occurs through ALK secondary mutations in clinical use. Here we examined the efficacy of a selective ALK inhibitor alectinib/CH5424802 in models of crizotinib resistance. Alectinib led to tumor size reduction in EML4-ALK-positive xenograft tumors that failed to regress fully during the treatment with crizotinib. In addition, alectinib inhibited the growth of some EML4-ALK mutant-driven tumors, including the G1269A model. These results demonstrated that alectinib might provide therapeutic opportunities for crizotinib-treated patients with ALK secondary mutations.
Keywords: ALK; ALK inhibitor; Alectinib; Drug resistance; NSCLC; Xenograft model.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical